Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent

Cell Research

Volumn 20, Issue 3, 2010, Pages 345-356

  Jiang, Hong ^a   Song, Ning ^a   Xu, Huamin ^a   Zhang, Shuzhen ^a   Wang, Jun ^a   Xie, Junxia ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Antioxidant; Divalent metal transporter 1; Iron; Iron regulatory protein; Oxidative stress; Parkinsons disease

Indexed keywords

ACETYLCYSTEINE; CATION TRANSPORT PROTEIN; DOPAMINE DERIVATIVE; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; REACTIVE OXYGEN METABOLITE; SOLUTE CARRIER FAMILY 11 (PROTON COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2; SOLUTE CARRIER FAMILY 11- (PROTON-COUPLED DIVALENT METAL ION TRANSPORTERS), MEMBER 2;

ANIMAL; ARTICLE; CELL LINE; DNA RESPONSIVE ELEMENT; METABOLISM; OXIDATIVE STRESS; RAT; UPREGULATION;

ACETYLCYSTEINE; ANIMALS; CATION TRANSPORT PROTEINS; CELL LINE; HYDROXYDOPAMINES; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RESPONSE ELEMENTS; UP-REGULATION;

RATTUS;

EID: 77949261597     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.20     Document Type: Article

References (46)

1. Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord 2006; 21:1299-1310.
2. Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 2006; 17:5-17.
3. Jiang H, Qian ZM, Xie JX. [Increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice]. Sheng Li Xue Bao 2003; 55:571-576.
4. Xie JX, Jiang H, Chen WF, Qian ZM. Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease. Exp Neurol 2003; 182:483-489.
5. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70 (Pt 2):1411-1417.
6. Salazar J, Mena N, Hunot S, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008; 105:18578-18583.
7. Wang J, Jiang H, Xie JX. Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. Neurochem Res 2004; 29:2239-2243.
8. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 2004; 1012:306-325.
9. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5:863-873.
10. Oakley AE, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007; 68:1820-1825.
11. Song N, Jiang H, Wang J, Xie JX. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamineinduced ferrous iron influx. J Neurosci Res 2007; 85:3118-3126.
12. Zhang S, Wang J, Song N, Xie J, Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol Aging 2009; 30:1466-1476.
13. Hentze MW, Kuhn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996; 93:8175-8182.
14. Nunez-Millacura C, Tapia V, Munoz P, Maccioni RB, Nunez MT. An oxidative stress-mediated positive-feedback iron uptake loop in neuronal cells. J Neurochem 2002; 82:240-248.
15. Regan RF, Chen M, Li Z, et al. Neurons lacking iron regulatory protein-2 are highly resistant to the toxicity of hemoglobin. Neurobiol Dis 2008; 31:242-249.
16. Regan RF, Li Z, Chen M, Zhang X, Chen-Roetling J. Iron regulatory proteins increase neuronal vulnerability to hydrogen peroxide. Biochem Biophys Res Commun 2008; 375:6-10.
17. Niles BJ, Clegg MS, Hanna LA, et al. Zinc deficiency-induced iron accumulation, a consequence of alterations in iron regulatory protein-binding activity, iron transporters, and iron storage proteins. J Biol Chem 2008; 283:5168-5177.
18. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002; 175:303-317.
19. Kaariainen TM, Piltonen M, Ossola B, et al. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine- induced parkinsonian models in rats and dopaminergic cell cultures. Brain Res 2008; 1203:149-159.
20. Weng Z, Signore AP, Gao Y, et al. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen- activated protein kinase signaling. J Biol Chem 2007; 282:34479-34491.
21. Ma ZG, Wang J, Jiang H, Liu TW, Xie JX. Myricetin reduces 6-hydroxydopamine-induced dopamine neuron degeneration in rats. Neuroreport 2007; 18:1181-1185.
22. Mandel S, Grunblatt E, Riederer P, et al. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 2003; 17:729-762.
23. Crawford GD Jr, Le WD, Smith RG, et al. A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J Neurosci 1992; 12:3392-3398.
24. Jiang H, Luan Z, Wang J, Xie J. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the sub stantia nigra of rats with iron-overload. Neurochem Int 2006; 49:605-609.
25. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004; 46:254-263.
26. Wang L, Wang W, Zhao M, Ma L, Li M. Psychological stress induces dysregulation of iron metabolism in rat brain. Neuroscience 2008; 155:24-30.
27. Galy B, Ferring-Appel D, Kaden S, Grone HJ, Hentze MW. Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. Cell Metab 2008; 7:79-85.
28. Huang E, Ong WY, Go ML, Connor JR. Upregulation of iron regulatory proteins and divalent metal transporter-1 isoforms in the rat hippocampus after kainate induced neuronal injury. Exp Brain Res 2006; 170:376-386.
29. Kato J, Kobune M, Ohkubo S, et al. Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp Hematol 2007; 35:879-887.
30. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 1998; 70:2492-2499.
31. Heikkila R, Cohen G. Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine. Science 1971; 172:1257-1258.
32. Saner A, Thoenen H. Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol 1971; 7:147-154.
33. Blum D, Torch S, Nissou MF, Benabid AL, Verna JM. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 2000; 283:193-196.
34. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S. 6-hydroxydopamine- induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 2006; 281:5373-5382.
35. Pantopoulos K, Weiss G, Hentze MW. Nitric oxide and oxidative stress (H2O2) control mammalian iron metabolism by different pathways. Mol Cell Biol 1996; 16:3781-3788.
36. Wang J, Chen G, Muckenthaler M, et al. Iron-mediated degradation of IRP2, an unexpected pathway involving a 2-oxoglutarate- dependent oxygenase activity. Mol Cell Biol 2004; 24:954-965.
37. Morris CM, Candy JM, Oakley AE, Bloxham CA, Edwardson JA. Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) 1992; 144:235-257.
38. Earl CD, Reum T, Xie JX, et al. Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data. Exp Brain Res 1996; 109:179-184.
39. Wang J, Jiang H, Xie JX. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci 2007; 25:2766-2772.
40. Zhou Y, Zhao ZQ, Xie JX. Effects of isatin on rotational behavior and DA levels in caudate putamen in Parkinsonian rats. Brain Res 2001; 917:127-132.
41. Jiang H, Li LJ, Wang J, Xie JX. Ghrelin antagonizes MPTPinduced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Exp Neurol 2008; 212:532-537.
42. Breuer W, Epsztejn S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem 1995; 270:24209-24215.
43. May JM, Qu ZC, Mendiratta S. Role of ascorbic acid in transferrin- independent reduction and uptake of iron by U-937 cells. Biochem Pharmacol 1999; 57:1275-1282.
44. Wetli HA, Buckett PD, Wessling-Resnick M. Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem Biol 2006; 13:965-972.
45. Armeni T, Damiani E, Battino M, Greci L, Principato G. Lack of in vitro protection by a common sunscreen ingredient on UVA-induced cytotoxicity in keratinocytes. Toxicology 2004; 203:165-178.
46. Xue L, Zhou B, Liu X, et al. Structurally dependent redox property of ribonucleotide reductase subunit p53R2. Cancer Res 2006; 66:1900-1905. (Pubitemid 43294895)